论文题目：Outcome of children with newly diagnosed acute lymphoblastic
leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China
第一作者：Lei Cui（崔蕾），Zhi-Gang Li（李志刚），Yi-Huan Chai（柴忆欢），
Jie Yu （于洁）, Ju Gao （高举）, Xiao-Fan Zhu（竺晓凡）, Run-Ming Jin （金润铭）, Xiao-Dong Shi （师晓东）, Le-Ping Zhang （张乐萍）, Yi-Jin Gao（高怡瑾）
发表杂志：American Journal of Hematology
Abstract：Acute lymphoblastic leukemia (ALL) is the most common malignancy among children. The trial Chinese Children Leukemia Group (CCLG)-ALL 2008 was a prospective multicenter clinical trial designed to improve treatment outcome of childhood ALL through the first nation-wide collaborative study in China. Totally 2231 patients were recruited from ten tertiary hospitals in eight cities. The patients were stratified according to clinical-biological characteristics and early treatment response. Standard risk (SR) and intermediate risk (IR) groups were treated with a modified BFM based protocol, whereas patients in high risk (HR) group received a more intensive maintenance treatment. Cranial irradiation was not applied except central nervous system leukemia at diagnosis. Minimal residual disease (MRD) monitoring with treatment adjustment was performed in two hospitals (the MRD group). Complete remission (CR) was achieved in 2100 patients (94.1%). Death during induction happened in 36 patients (1.6%), and another 64 patients (2.9%) died due to non-relapse causes after achieving CR. At five years, the estimate for overall survival (OS) and event-free survival (EFS) of the whole group was 85.3% and 79.9%, respectively. The cumulative incidence of relapse (CIR) was 15.3% at five years. The outcome of the MRD group is better than the non-MRD group (5y-EFS: 82.4% vs 78.3%, P = 0.038; 5y-CIR: 10.7% vs 18.0%, P < 0.001). Our results demonstrated that large-scale multicenter trial for pediatric ALL was feasible in China, and the survival outcome was encouraging. MRD-based risk stratification might improve the treatment outcome for childhood ALL.